Topical Immuonosuppressant Drugs in Spring Catarrh
Vernal Keratoconjunctivitis
About this trial
This is an interventional treatment trial for Vernal Keratoconjunctivitis focused on measuring Resistant spring catarrh, Cyclosporine A, Tacrolimus
Eligibility Criteria
Inclusion Criteria:
- Patients suffering from Vernal Keratoconjunctivitis refractory to conventional treatments (Topical Anti-histaminic agents, Mast-cell stabilizer and steroids) are included.
Exclusion Criteria:
- Contact lens wearer. Patient with one functioning eye. Patients with any other active ocular inflammatory conditions. Patients with hypersentivity reaction to either Cyclosporine A or Tacrolimus. Loss of 2 or more follow up visits.
Sites / Locations
- Assiut University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Topical steroids
Topical Cyclosporine A
Topical Tacrolimus
Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by 4 times daily for 2 weeks, then twice daily for 2 weeks and finally once daily for 2 weeks.
Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by Topical Cyclosporine A 2% Topical eye drops 2 times per day for 6 weeks.
Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by Topical Tacrolimus A 0.3% Topical eye drops 2 times per day for 6 weeks.